Skip to content

Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Nov 10, 2015
SAN DIEGO, Nov. 10, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported financial results for the third quarter ended September 30, 2015, and provided a corporate update. "On October 27, we announced a plan to improve efficiencies and reduce costs as we chart a new course for Arena with our refocusing effort," said...
Nov 4, 2015
SAN DIEGO, Nov. 4, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it will host a conference call and webcast at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) on Tuesday, November 10, 2015, to discuss third quarter 2015 financial results and provide a corporate update. Arena will issue a press release with its...
Nov 2, 2015
WOODCLIFF LAKE, N.J., and SAN DIEGO, Nov. 2, 2015 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that six posters regarding lorcaserin HCl data will be presented during ObesityWeekSM. Hosted by The Obesity Society and the American Society for Metabolic and Bariatric Surgery, the meeting is taking place Nov...
Oct 29, 2015
SAN DIEGO, Oct. 29, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today the initiation of patient dosing in a Phase 1b multiple-ascending dose clinical trial of APD371, a selective and potent agonist of the cannabinoid 2 (CB2) receptor. This randomized, double-blind, placebo-controlled Phase 1b clinical trial will...
Oct 27, 2015
SAN DIEGO, Oct. 27, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced plans to improve efficiencies and reduce costs as it focuses on the advancement of its research and development priorities. Arena intends to focus on its key strengths by concentrating near-term activities and resources primarily on: ...
Oct 27, 2015
SAN DIEGO and WOODCLIFF LAKE, N.J., Oct. 27, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today that the US Patent and Trademark Office granted Arena US Patent No. 9,169,213, entitled "Method of Weight Management," covering BELVIQ® (lorcaserin HCl) for chronic weight management. "This patent ...
Oct 5, 2015
SAN DIEGO, Oct. 5, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that, at the request of the Board of Directors, Jack Lief, Arena's President and Chief Executive Officer, has retired from the company, including its Board of Directors. Dr. Harry F. Hixson, a director of Arena since 2004, has been appointed to serve ...
Sep 24, 2015
WOODCLIFF LAKE, N.J. and SAN DIEGO, Sept. 24, 2015 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that lorcaserin HCl data will be presented at the following medical meetings: 2015 Annual Meeting of the American College of Clinical Pharmacology, taking place September 27-29, 2015, in San Francis...
Sep 3, 2015
SAN DIEGO, Sept. 3, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview and update at the Wells Fargo 2015 Healthcare Conference on Wednesday, September 9, 2015, at 10:00 a.m. Eastern Time (7:00 a.m. Pacific Time), at the Hyatt Regency in Boston, Massachusetts...
Aug 5, 2015
SAN DIEGO, Aug. 5, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported financial results for the second quarter ended June 30, 2015, and provided a corporate update. "We have continued to advance our deep clinical-stage pipeline, as evidenced by the recent initiation of a Phase 2 proof-of-concept clinical trial of ...
Jul 30, 2015
SAN DIEGO, July 30, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it will host a conference call and webcast at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) on Wednesday, August 5, 2015, to discuss second quarter 2015 financial results and provide a corporate update. Arena will release its financial results...
Jul 29, 2015
SAN DIEGO, July 29, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today the initiation of patient screening in a Phase 2 proof-of-concept clinical trial of APD334 in ulcerative colitis. Discovered by Arena, APD334 is an oral, investigational, Sphingosine 1-Phosphate Subtype 1 (S1P1) receptor modulator with therapeutic po...
Jun 16, 2015
SAN DIEGO, June 16, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that Robert E. Hoffman, Senior Vice President, Finance and Chief Financial Officer, has decided to leave the company after nearly 18 years of service to pursue another opportunity in the biotechnology industry. Mr. Hoffman is expected to remain in hi...
Jun 4, 2015
WOODCLIFF LAKE, N.J. and SAN DIEGO, June 4, 2015 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the following poster regarding lorcaserin HCl will be presented at American Diabetes Association's 75th Scientific Sessions taking place June 5-9, 2015, in Boston, Massachusetts: Impact of ...
May 26, 2015
SAN DIEGO, May 26, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview and update at the Jefferies 2015 Global Healthcare Conference on Monday, June 1, 2015, at 10:30 a.m. Eastern Time (7:30 a.m. Pacific Time), at the Grand Hyatt in New York, New York. ...
= add release to Briefcase